Weekly Recap | AMLX.US +78.73%, Phase 3 win sparks rally

The Week

Amylyx Pharmaceuticals (AMLX.US) surged 78.73% this week, closing at $38.66 against a backdrop of a 1.43% decline in the S&P 500, outperforming the broad market by roughly 80.16 percentage points. The week’s trajectory was anything but linear. Monday (Aug 17) saw a quiet session with the stock oscillating between $21.28 and $22.47. The narrative shifted dramatically on Tuesday (Aug 18), when shares gapped up and rocketed to a close of $35.11 on massive volume. The rally extended into Wednesday and Thursday (Aug 19-20), pushing the stock to a 60-day high of $41.14, before a modest pullback on Friday (Aug 21) saw it settle at $38.66.

Key Events

Amylyx’s week was defined by a blockbuster clinical readout followed immediately by a massive capital raise. On Tuesday, the company announced that its lead candidate, Avexitide, met the primary endpoint in the Phase 3 LUCIDITY trial for post-bariatric hypoglycaemia (PBH), demonstrating a 55% reduction in severe hypoglycaemic events with a clean safety profile. The data sent the stock soaring over 60% in a single session.

However, hours after the data drop, management launched a $350 million public offering, which was swiftly upsized to $500 million by Wednesday evening. The deal was priced at $35.50 per share, with the company netting approximately $472 million. While the dilutive move caused a brief dip in after-hours trading, the stock held firmly above the offer price, signalling that the market’s excitement over Avexitide’s potential far outweighed the near-term dilution.

Analyst Ratings

Coverage on Amylyx remains overwhelmingly positive, with 12 analysts weighing in. The consensus is a ‘strong buy,’ driven by 11 strong buy ratings and a single hold rating. No analyst rates the stock under or sell. The consensus target price sits at $42.18, offering a roughly 9.1% upside from the week’s closing price of $38.66. Individual targets range widely from $20 to $55, reflecting a notable divergence of opinion on the stock’s fair value. Within the pharmaceutical industry, Amylyx’s ranking stands at 27 out of 201 companies.

The Week Ahead

Following a week of company-specific fireworks, the near-term focus will pivot to the macro environment. Tuesday (Aug 25) brings a slate of US housing data, including the FHFA House Price Index, the S&P/Case-Shiller Home Price Index, and new home sales figures, alongside the Consumer Confidence Index. These data points could sway risk appetite for high-beta sectors like biotech. With the $500 million offering now closed, market participants will be watching for any corporate updates on the regulatory pathway and commercialisation strategy for Avexitide.

In Short

This week, Amylyx delivered a watershed moment, with Phase 3 success for Avexitide translating into a historic share-price rally. The market’s conviction was tested by a $500 million overnight offering, yet the stock remained firmly above the deal price, highlighting the strength of the underlying bid. The tension between a ‘strong buy’ consensus with a target above spot and the reality of dilution creates a balanced forward narrative. The key question now is whether the company can convert this clinical win and fortified balance sheet into a real-world commercial franchise.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.